Citation: | JIN Yu, YAO Dongning, SHAO Rong. Development and regulation of biological products in China[J]. Journal of China Pharmaceutical University, 2014, 45(3): 378-382. DOI: 10.11665/j.issn.1000-5048.20140323 |
[1] |
Zhan ZS,Ji QS,Pu CY,et al.The development status and prospect of biotechnology drugs[J].J Pract Med Pharm(实用医药杂志),2011,28(2):168-170.
|
[2] |
Li G.Global bio pharmaceutical industry prospects in 2012(2012年全球生物制药业前景光明)[N].China Pharm News(中国医药报),2012-03-28(A06).
|
[3] |
Wen SM.The global development of the biopharmaceutical industry[J].China Biotechnol(中国生物工程杂志),2006,26(1):92-96.
|
[4] |
Wang Y,Wu WJ,Li Q,et al.The research progress and trend of biotech drugs in recent years in China[J].Pharm Biotechnol(药物生物技术),2013,20(1):1-11.
|
[5] |
Chang WH,Han P,Cao LZ.The past 30 years and the future of drug registration and R&D in China(1)[J].Chin J New Drugs(中国新药杂志),2010,19(23):2 127-2 131.
|
[6] |
Jia LL,Yang Y,Dong GM.Study on improvement of national lot release regulations on biological products[J].Chin Pharm Aff(中国药事),2010,24(6):523-530.
|
[7] |
Wang XJ,Cao Y,Guo ZP.The historical evolution of Chinese biological products national standard[J].Chin J Biol(中国生物制品学杂志),2013,26(4):582-584.
|
[8] |
Chen XY,Dong Z,Hou YF.The history of security control and adverse reaction monitoring to the marketed Chinese biological product[J].Pharm Biotechnol(药物生物技术),2008,15(5):407-410.
|
[9] |
Tang RY,Zhu CH.Analysis of China′s biopharmaceutical industry status quo and development constraints[J].Mod Prev Med(现代预防医学),2011,38(21):4 406-4 408,4 416.
|